MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
MediWound (MDWD) Q3 2026 Earnings Call Transcript
MediWound Ltd. Q3 2026 Earnings Call Summary
What MediWound (MDWD) Said on Its Q3 Earnings Call
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
MediWound: Q3 Earnings Snapshot
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript
MediWound Q3 2026 Earnings Call Transcript
CORRECTION: MediWound Q3 EPS $(0.65) Beats $(0.71) Estimate, Sales $3.600M Miss $6.728M Estimate
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
MediWound Announces $15M Bought Deal Offering Of 1.2M Shares At $12.50/Share
MediWound to Report Third Quarter 2026 Financial Results
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound (MDWD) Q2 2026 Earnings Call Transcript
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $30
MediWound Ltd. Q2 2026 Earnings Call Summary
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.